Press release: 2026-05-06

Cordicity Announces Oversubscribed SEK 7 Million Seed Round to Accelerate Clinical Validation and CE Marking

Cordicity has successfully closed an oversubscribed seed financing round totaling SEK 7 million. The investment will support expansion of the company’s team, continued clinical validation, and regulatory activities as the company advances toward CE marking and commercialization of its first product.

The round was led by Almi Invest and East Sweden Capital, with follow-on investment from LiU Invest and new investments from Cygne Invest, Henrik Lewander Invest and Management, HMBV, and MThor Holding.

Today, stroke risk assessment in atrial fibrillation patients is largely based on generalized clinical scoring systems, which may fail to capture an individual patient’s true risk profile. Cordicity’s platform is designed to provide a more patient-specific assessment using existing cardiac CT data, with the ambition to support improved treatment decisions and preventive care. The growing global burden of cardiovascular disease, combined with increasing adoption of advanced imaging and AI-supported diagnostics, is expected to drive demand for more precise and personalized decision-support solutions in healthcare.

The company is currently in an early commercialization phase focused on clinical validation studies, regulatory preparations, and pilot collaborations with healthcare providers and strategic partners. Cordicity has also received significant research and innovation funding, including support from Vinnova.

“We are very pleased to have such a strong group of investors supporting our next phase of growth. This financing enables us to accelerate product development and move closer to delivering clinical impact for patients and healthcare providers,” says Linus Ohlsson, CEO and co-founder